# reload+after+2024-01-21 15:33:38.928124
address1§124 Dvora Hanevi’a Street
city§Tel Aviv
zip§6944020
country§Israel
phone§972 3 914 8213
website§https://www.tevapharm.com
industry§Drug Manufacturers—Specialty & Generic
sector§Healthcare
longBusinessSummary§Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also manufactures and sells active pharmaceutical ingredients, as well as provides contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. In addition, it focuses on the central nervous system (CNS), pain, respiratory, and oncology areas. The company's products portfolio in the CNS field comprises Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; and AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; respiratory therapeutic area includes ProAir RespiClick, QVAR, ProAir Digihaler, AirDuo Digihaler, ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease; and oncology therapeutic field consists of Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration with MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia, as well as a collaboration with Sanofi to co-develop and co-commercialize TEV-48574 asset, a novel anti-TL1A therapy for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.
fullTimeEmployees§34004
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Eliyahu Sharon Kalif', 'age': 50, 'title': 'Executive VP & CFO', 'yearBorn': 1973, 'fiscalYear': 2022, 'totalPay': 2014622, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Eric  Drape', 'age': 61, 'title': 'Executive Vice President of Global Operations', 'yearBorn': 1962, 'fiscalYear': 2022, 'totalPay': 1906838, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Mark  Sabag', 'age': 52, 'title': 'Executive Vice President of International Markets Commercial', 'yearBorn': 1971, 'fiscalYear': 2022, 'totalPay': 1923938, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Richard D. Francis', 'age': 55, 'title': 'President, CEO & Director', 'yearBorn': 1968, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Amir  Weiss', 'age': 46, 'title': 'Senior VP & Chief Accounting Officer', 'yearBorn': 1977, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ran  Meir', 'title': 'Head of Investor Relations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dov  Bergwerk', 'title': 'Acting Chief Legal Officer & Corporate Secretary', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Kathleen  Veit', 'title': 'Senior Vice President, Global Compliance & Ethics Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Vikki  Conway', 'title': 'Acting Head of Global Human Resources', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Kevin C. Mannix', 'title': 'Senior Vice President of Investor Relations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§9
boardRisk§3
compensationRisk§4
shareHolderRightsRisk§5
overallRisk§5
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
exDividendDate§1511740800
payoutRatio§0.0
fiveYearAvgDividendYield§2.95
beta§1.094
priceToSalesTrailing12Months§0.8315714
currency§USD
dateShortInterest§1702598400
forwardEps§2.42
pegRatio§2.94
exchange§NYQ
quoteType§EQUITY
shortName§Teva Pharmaceutical Industries 
longName§Teva Pharmaceutical Industries Limited
firstTradeDateEpochUtc§382717800
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§3c9a2e4e-3f23-3197-9f8f-db8bf33dae35
gmtOffSetMilliseconds§-18000000
targetHighPrice§14.0
targetLowPrice§9.0
targetMeanPrice§11.3
targetMedianPrice§11.0
recommendationMean§2.6
recommendationKey§hold
numberOfAnalystOpinions§10
quickRatio§0.494
earningsGrowth§0.4
grossMargins§0.45839
ebitdaMargins§0.24632
trailingPegRatio§1.8426
